Contact for more Information
Technology Alerts minus

Sign up to receive TIDO’s monthly newsletter highlighting new Children’s Hospital technologies and research and development partnership opportunities.

sign me up
Related Informationminus

Lodamin for Treating Eye Diseases

Lodamin is a novel anti-angiogenic drug and a non-toxic derivative of TNP-470.

send to a friend

CMCC 1601

Lodamin for the Treatment of Cancer

Inventors: M. Folkman, Ofra Ratsaby-Benny

Categories: Therapeutics

SubCategories: Neurology/Neuroscience, Oncology/Hematology, Ophthalmology

Keywords: Anti-angiogenesis

Invention Description:

Originally identified in the late Dr. Judah Folkman's laboratory, TNP-470 is a low molecular weight synthetic analogue of Fumagillin, a product secreted by a fungus. It was one of the most potent anti-angiogenic compounds and possessed the broadest anti-cancer spectrum of any known agent. TNP-470 showed promise in oncology development but Phase II trials were interrupted because of reversible neurotoxicity, poor oral availability and a short half-life.

Dr. Ofra Benny-Ratsaby has developed a formulation, called Lodamin, which potentially solves all of these limitations. Lodamin is a conjugate of TNP-470 to PEG and PLA polymers and forms micelles with TNP-470 at its core, allowing for oral availability and for delivery to the tumor where the drug is slowly released. Lodamin exhibited anti-angiogenic activity in vivo and inhibited primary tumor growth in mouse models of melanoma, lung, breast, brain and ovarian cancers by more than 80% without neurotoxicity or other adverse events. Importantly, Lodamin also prevented melanoma-derived liver metastases, a condition which is incurable in humans, and prolonged survival in mice.


These in vivo results indicate that Lodamin could be a clinically useful angiogenesis inhibitor with potential broad treatment applications in angiogenesis-dependent diseases such as cancer, endometriosis, obesity, macular degeneration, alone or in combination with other anti-angiogenic agents or with chemotherapy.

Competitive Advantages:

• Lodamin is the first oral non-toxic derivative of TNP-470: MetAp2 inhibitor • Expected to be safe: no crossing of blood brain barrier; no observed neurotoxicity, weight loss or tissue abnormalities; polymers are biocompatible, nonimmunogenic and FDA approved • Prevents liver metastases without liver toxicity, and prolongs survival • Improved potent anti-cancer efficacy due to preferential accumulation in tumor tissue, slow release and long blood circulation time of at least 72hrs • Potential treatment for indications beyond oncology: inhibited lesion size by 71% in a mouse model of macular degeneration when administered orally • Inhibits both capillary growth and leakage of fluid • Several hundred patients treated with parent molecule TNP-470 • Composition of matter and method of use claims pending

Business Opportunity:

Exclusive license available

Key Publications: Nature Biotechnology. 2008 Jul; 26(7):799-807.
2 issued US patents and other pending and allowed in foreign jurisdictions

IPStatus: Patented

Terms and Conditions children's hospital
Site Designed and Developed by Genuine